Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
Curr Opin Support Palliat Care. 2019 Sep;13(3):143-151. doi: 10.1097/SPC.0000000000000447.
Many patients with interstitial lung diseases (ILDs), especially fibrotic ILDs, experience chronic cough. Cough has a major impact on wellbeing, affecting both physical and psychological aspects of life. The pathophysiology of cough in ILDs is poorly understood and currently no good antitussive therapy exists.
Research on cough in ILDs is increasing. A recent proof-of-concept study with nebulized sodium cromoglycate for patients with idiopathic pulmonary fibrosis (IPF)-related cough showed a promising effect on cough. Observational data suggest that antifibrotic pirfenidone might reduce cough in IPF. Studies on the effect of acid inhibition on cough in ILDs show contradicting results.
The first steps in analyzing new treatment options for chronic cough in patients with ILDs, especially in IPF, have been taken, but an effective treatment is still lacking.
许多间质性肺疾病（ILDs）患者，尤其是纤维化ILDs 患者，会经历慢性咳嗽。咳嗽对患者的整体健康有重大影响，影响生活的身体和心理两方面。ILDs 患者咳嗽的病理生理学机制尚未完全阐明，目前尚无有效的镇咳治疗方法。
ILDs 相关咳嗽的研究在不断增加。最近一项关于雾化色甘酸钠治疗特发性肺纤维化（IPF）相关咳嗽的概念验证研究显示出对咳嗽有良好的疗效。观察性数据表明，抗纤维化药物吡非尼酮可能会减少 IPF 患者的咳嗽。关于抑酸对 ILDs 咳嗽影响的研究结果相互矛盾。
已经对ILDs 患者，特别是 IPF 患者慢性咳嗽的新治疗选择进行了初步分析，但仍缺乏有效的治疗方法。
